11 chapters on drug classes: 8 on oral agents (biguanides, sulfonylureas, glinides, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, alpha-glucosidase inhibitors, and imeglimin, bromocriptine and hydroxychloroquine) and 3 on injectables (insulin, insulin analogs, GLP-1 receptor agonists).
Appendix chapters on quick drug reference tables (mechanisms, doses, side effects, monitoring tips) and clinical algorithms and flowcharts.
5 special-scenario chapters, including gestational diabetes with comparison tables on insulin pharmacokinetics and continuous glucose monitoring metrics.
Fixed-dose combinations and an escalation ladder for stepping up treatment.
7 sections and 27 chapters, from the pathophysiology of diabetes to patient communication.